Therapeutic Strategy Details
| Strategy ID: | S12 |
| Strategy: | Anti-platelet aggregation |
| Other Terms: | None |
| Related Targets: | Platelet GPIbα |
| Related Drugs: | aspirin/clopidogrel; ticagrelor |
| Mechanism: | Platelet cargo, platelet adhesion and platelet activation but not platelet aggregation were identified as pivotal for NASH and subsequent hepatocarcinogenesis. |
| Reference (PMIDs): | 18596193; 30936549 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D002 | Acetaminophen | Chemical drug | DB00316 | PTGES3 inhibitor; TRPV1 activator | Antipyretic drug; non-narcotic analgesic | Under clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D033 | Bezafibrate | Chemical drug | DB01393 | PPARA agonist; PPARD agonist; PPARG agonist; NR1I2 partial agonist | Improve insulin resistance; Anti-inflammatory | Under clinical trials | Details |
| D092 | Curcumin | Chemical drug | DB11672 | PPARG; COX inhibitor | Anticancer agent; NSAID | Under clinical trials | Details |
| D096 | Dabigatran Etexilate | Chemical drug | DB06695 | thrombin inhibitor | -- | Under clinical trials | Details |
| D105 | DHA | Chemical drug | DB03756 | PPARA ligand; PPARG ligand | Anti-inflammatory | Under clinical trials | Details |
| D266 | Pentoxifylline | Chemical drug | DB00806 | ADORA2A antagonist; ADORA1 antagonist; PDE4A inhibitor; PDE3B inhibitor; PDE4B inhibitor; PDE5A inhibitor; PDE8A inhibitor; PDE4C inhibitor; PDE11A inhibitor; PDE7A inhibitor; PDE7B inhibitor; PDE4D inhibitor; PDE3A inhibitor | Anti-inflammatory; Cardiovascular drug | Under clinical trials | Details |
| D318 | Salsalate | Chemical drug | DB01399 | PTGS2 inhibitor; PTGS1 inhibitor | NSAID | Under clinical trials | Details |
| D385 | Vitamin B6 | Supplement | DB00165 | PDXK ligand | -- | Under clinical trials | Details |
| D474 | Cilostazol | Chemical drug | DB01166 | -- | -- | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0018 | DB00054 | approved | biotech | Abciximab | Therapeutic strategy associated | Details |
| R0019 | DB00063 | approved; investigational | biotech | Eptifibatide | Therapeutic strategy associated | Details |
| R0043 | DB00132 | approved; investigational; nutraceutical | small molecule | alpha-Linolenic acid | Therapeutic strategy associated | Details |
| R0054 | DB00154 | investigational; nutraceutical | small molecule | Dihomo-gamma-linolenic acid | Therapeutic strategy associated | Details |
| R0056 | DB00159 | approved; nutraceutical | small molecule | Icosapent | Therapeutic strategy associated | Details |
| R0078 | DB00208 | approved | small molecule | Ticlopidine | Therapeutic strategy associated | Details |
| R0096 | DB00261 | approved | small molecule | Anagrelide | Therapeutic strategy associated | Details |
| R0101 | DB00278 | approved; investigational | small molecule | Argatroban | Therapeutic strategy associated | Details |
| R0111 | DB00310 | approved | small molecule | Chlorthalidone | Therapeutic strategy associated | Details |
| R0134 | DB00374 | approved; investigational | small molecule | Treprostinil | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | Details |
| A01756 | 34628383 | Georgian Med News | THE INFLUENCE OF HYPERCHOLESTEROLEMIA AND CONCOMITANT STATIN THERAPY ON THE STATE OF PLATELET-PLASMA HEMOSTASIS IN PATIENTS WITH ESSENTIAL HYPERTENSION AND NON-ALCOHOLIC FATTY LIVER DISEASE. | Details |
| A03935 | 33813276 | Biochem Biophys Res Commun | Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD. | Details |
| A05662 | 33169375 | Br J Pharmacol | Exploiting oxidized lipids and the lipid-binding GPCRs against cardiometabolic diseases. | Details |
| A11027 | 31077838 | Clin Gastroenterol Hepatol | Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. | Details |
| A11327 | 30936549 | Nat Med | Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. | Details |
| A14947 | 29161233 | J Basic Clin Physiol Pharmacol | Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease. | Details |
| A16899 | 28104990 | World J Gastroenterol | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. | Details |
| A17164 | 27938560 | Zhonghua Gan Zang Bing Za Zhi | [Effect of targeted inhibition of hypoxia-inducible factor-1α by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole on the progression of non-alcoholic fatty liver disease in rats]. | Details |
| A17616 | 27713972 | Food Funct | Vascular- and hepato-protective effects of passion fruit seed extract containing piceatannol in chronic high-fat diet-fed rats. | Details |
| A19920 | 26265520 | Arch Iran Med | PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. | Details |
| A23709 | 23548197 | J Hepatol | Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. | Details |
| A24832 | 22450341 | Hormones (Athens) | Adiponectin: regulation of its production and its role in human diseases. | Details |
| A24870 | 22418887 | Semin Liver Dis | Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. | Details |
| A25190 | 22105182 | J Clin Gastroenterol | Coronary artery stents and antiplatelet therapy in patients with cirrhosis. | Details |
| A25520 | 21748765 | Hepatology | Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. | Details |
| A27348 | 18596193 | Gut | Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. | Details |
| A27746 | 17539815 | Hepatol Res | A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. | Details |
| A28068 | 16531961 | Ann Hepatol | Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. | Details |
| A34863 | 22403205 | J Am Board Fam Med | Navigating change: how outreach facilitators can help clinicians improve patient outcomes. | Details |